Cytokinetics Inc (CYTK) Stock AnalysisCYTKStock AnalysisCytokinetics Inc

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cytokinetics Inc is currently not a strong buy due to its low RSI of 25.889, indicating it is oversold, and the significant insider selling activity, where the CEO sold 7,500 shares. However, the stock has a positive long-term outlook with a projected price increase of nearly 40% and a solid 1-year change of +45.28%.

8 analysts cover CYTK: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 89.33.